Jia Jie Biomedical Co., Ltd. logo

Jia Jie Biomedical Co., Ltd. (4109)

Market Closed
7 Aug, 05:30
TWSE TWSE
NT$
11. 25
+0.05
+0.4464%
NT$
- Market Cap
- P/E Ratio
1.19% Div Yield
263,100 Volume
- Eps
NT$ 11.2
Previous Close
Add Transaction
Day Range
11.2 11.45
Year Range
10.35 18.8
Want to track 4109 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

4109 closed Friday higher at NT$11.25, an increase of 0.4464% from Thursday's close, completing a monthly decrease of -0.8811% or -NT$0.1. Over the past 12 months, 4109 stock lost -25.2492%.
4109 pays dividends to its shareholders, with the most recent payment made on Oct 23, 2025. The next announced payment will be in In 2 months on Oct 23, 2026 for a total of NT$0.2.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Jia Jie Biomedical Co., Ltd. has completed 13 stock splits, with the recent split occurring on Mar 21, 2019.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on JPX (JPY).

4109 Chart

Jia Jie Biomedical Co., Ltd. (4109) FAQ

What is the stock price today?

The current price is NT$11.25.

On which exchange is it traded?

Jia Jie Biomedical Co., Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 4109.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.19%.

What is its market cap?

As of today, no market cap data is available.

Has Jia Jie Biomedical Co., Ltd. ever had a stock split?

Jia Jie Biomedical Co., Ltd. had 13 splits and the recent split was on Mar 21, 2019.

Jia Jie Biomedical Co., Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Ms. Aki Hashimoto CEO
TWSE Exchange
TW0004109004 ISIN
US Country
694 Employees
29 Sep 2026 Last Dividend
- Last Split
- IPO Date

Overview

Stella Chemifa Corporation, originally known as Hashimoto Chemical Corporation before its name change in 1997, is a longstanding entity established in 1916. Positioned in Osaka, Japan, the company operates on a global scale, specializing in the manufacturing and selling of inorganic fluorine compounds. Its significant role in the chemical industry is highlighted by its extensive product range, catering to various sectors, including semiconductors, liquid crystals, optical materials, batteries, and even the field of nuclear energy and medical treatments. Moreover, Stella Chemifa extends its expertise to the transportation of special chemical substances, high-pressure gas, hazardous materials, and related products, showcasing a comprehensive involvement in the chemical sector. Notably, the company is actively engaged in the development of innovative treatments, such as Boron Neutron Capture therapy, contributing to cancer treatment advancements.

Products and Services

  • Hydrofluoric Acid and Derivatives: The company produces hydrofluoric acid, buffered hydrofluoric acid, and etching solutions, primarily used in the manufacturing of semiconductors and liquid crystal products.
  • Fluorides for Optical Materials: Stella Chemifa offers a variety of fluorides including calcium, aluminum, lithium, strontium, barium, magnesium, and lead fluoride which are utilized in the production of optical materials.
  • Lithium Hexafluorophosphate for Batteries: This compound is specifically catered for use in battery applications, underlining the company's contribution to the energy sector.
  • Reactive Catalysts: A range of boron trifluoride complexes such as boron trifluoride diethyl ether, boron trifluoride dimethyl ether, among others, are offered for use as reactive catalysts in various chemical processes.
  • Surface Treatment and CFC Alternatives: Products like anhydrous hydrofluoric acid and 55% hydrofluoric acid are provided for applications in surface treatment and as alternatives for chlorofluorocarbons (CFCs).
  • Nuclear Energy Applications: The company supplies potassium fluoroborate and boric acid, substances integral to nuclear energy applications.
  • GMP-Compliant Products: Stella Chemifa manufactures tin fluoride (II) USP, adhering to Good Manufacturing Practice (GMP) standards, highlighting its capability to meet rigorous quality criteria.
  • Additional Chemical Products: A wide assortment including fluorosilicic acid, various fluoroborates, and fluorides, demonstrates the company’s extensive chemical manufacturing capabilities.
  • Specialized Transport Services: Beyond just manufacturing, Stella Chemifa offers transportation services for special chemical substances, high-pressure gas, hazardous materials, ensuring the safe and secure handling of chemicals.
  • Cancer Treatment Development: Actively involved in medical research, the company is developing Boron Neutron Capture therapy, a promising cancer treatment, showcasing its commitment to healthcare advancements.

Contact Information

Address: Meiji Yasuda Seimei Osaka Midosuji Bldg, Osaka, Japan, 541-0044
Phone: 81 6 4707 1511